SYMATESE and Nordic Pharma reinforce partnership

SYMATESE welcomes Nordic Pharma’s recent announcement of the European launch of Lacrifill®, a novel dry eye therapy leveraging SYMATESE’s proprietary Hyaluronic Acid technological platform, manufactured in France by SYMATESE. Lacrifill® was already successfully launched in the United States and addresses a market of more than 16 million patients.

Read the full Press release